Clinical Report: IPF Cough: Opioid-Based Approach Tested

Overview

A phase 2b randomized clinical trial evaluated the efficacy of oral nalbuphine in reducing cough frequency in patients with idiopathic pulmonary fibrosis (IPF) using continuous 24-hour digital cough monitoring. Significant dose-dependent reductions in cough frequency were observed, with the highest dose achieving a 60% reduction compared to placebo.

Background

Chronic cough is a prevalent and distressing symptom in patients with idiopathic pulmonary fibrosis (IPF), significantly impacting their quality of life. Current treatment options for cough in IPF are limited, with no U.S.-approved antitussive specifically for this condition. The recent trial exploring opioid-based therapies represents a potential advancement in managing this challenging symptom.

Data Highlights

Key Findings

• The phase 2b CORAL trial included 165 patients with IPF and chronic cough.
• Median age of participants was 71 years, with 72% male and 77% on antifibrotic therapy.
• Significant reductions in cough frequency were observed with nalbuphine doses of 54 mg and 108 mg.
• Adverse events were mostly mild, including nausea and dizziness, primarily during dose titration.
• The trial duration was limited to 6 weeks, necessitating further studies for long-term efficacy.
• Primary outcome was the relative change from baseline in objectively measured 24-hour cough frequency at week 6.
• Secondary outcomes included patient-reported cough frequency, cough severity, and health-related quality of life.

Clinical Implications

The findings suggest that nalbuphine may provide a new therapeutic option for managing chronic cough in IPF patients. Clinicians should consider the potential benefits and risks of opioid-based treatments in this population, particularly given the limited existing options and the risk of opioid addiction.

Conclusion

The trial results indicate that nalbuphine may significantly reduce cough frequency in patients with IPF, warranting further investigation in larger studies to confirm these findings and assess long-term safety.

References

1. JAMA, 2026 -- Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough: Research Summary
2. American Journal of Respiratory and Critical Care Medicine -- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
3. Intensive Care Medicine — Timed Administration of Intravenous Opioids
4. Critical Care (Springer) — New persistent opioid use among ICU survivors after discharge: incidence, predictors, and nationwide cohort analysis
5. American Journal of Epidemiology — Opioid-Related Harms and the Impact of Abuse-Deterrent Formulations in North Carolina: A Study from 2010 to 2018
6. The ASCO Post — EXPECT QUESTIONS ABOUT THE RISK OF OPIOID ADDICTION
7. Timed Administration of Intravenous Opioids
8. New persistent opioid use among ICU survivors after discharge: incidence, predictors, and nationwide cohort analysis
9. Opioid-Related Harms and the Impact of Abuse-Deterrent Formulations in North Carolina: A Study from 2010 to 2018
10. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine
11. Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough: Research Summary | Trials | JAMA | JAMA Network
12. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial - PubMed